• PDG9 PREVALENCE OF POLYMEDICATION IN POOR POPULATION OF THE CARIBBEAN REGION OF COLOMBIA

    May 1, 2020, 00:00

  • PMS95 RHEUMATOID ARTHRITIS TREATMENT PROFILE IN THE BRAZILIAN PUBLIC HEALTH SYSTEM

    May 1, 2020, 00:00

  • PCN16 RESECTION FOR RECURRENT BRAIN METASTASES: A SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2020, 00:00

  • PDB107 ASSESSING ASYMMETRICAL PRESCRIBING OF ANTIDIABETIC DRUGS RELATIVE TO DIAGNOSIS OF NAFLD

    May 1, 2020, 00:00

  • PDG6 HEALTH JUDICIALIZATION IN BRAZIL: IMPACT OF MIGLUSTATE MEDICINE OBLIGATION FOR PATIENTS WITHOUT OFFICIAL INDICATION OF USE, IN 2019 IN BRAZIL

    May 1, 2020, 00:00

  • PIN14 UPDATING THE CMS MAJOR DIAGNOSTIC CATEGORIES (MDC) TO ALIGN WITH A PATHOPHYSIOLOGICAL MODEL OF DISEASE: IMPLICATIONS FOR RESEARCH AND CLINICAL CARE RESOURCE ALLOCATION

    May 1, 2020, 00:00

  • Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019

    May 1, 2020, 00:00

  • PMD34 DEEP JOINT INFECTION COMPARISON BETWEEN SIMULTANEOUS AND STAGED BILATERAL TOTAL KNEE ARTHROPLASTY

    May 1, 2020, 00:00

  • PGI20 THE IMPACT OF ULCERATIVE COLITIS ON WORK PRODUCTIVITY: A SYSTEMATIC LITERATURE REVIEW

    May 1, 2020, 00:00

  • PMU8 EVALUATION OF THE IMPACT OF AN INPATIENT DISCHARGE CARE PLANNING INTERVENTION ON HOSPITAL 30-DAY READMISSIONS AND COSTS IN A MEDICARE POPULATION

    May 1, 2020, 00:00

  • PIH38 MEASURING A RISK OF AND FACTORS ASSOCIATED WITH IN-HOME TOBACCO SMOKE EXPOSURE IN A US PEDIATRIC SAMPLE: HOUSEHOLD ECONOMICS AND VOLATILE ORGANIC COMPOUND METABOLITE DETECTION

    May 1, 2020, 00:00

  • PMS61 DISABILITY AND DEPRESSION IN LOW BACK PAIN. EVIDENCE FROM A COHORT STUDY

    May 1, 2020, 00:00

  • PMU19 FIRST LINE TREATMENT WITH NATALIZUMAB REDUCES HEALTHCARE RESOURCE USE AND IMPAIRMENT OF WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENTS COMPARED TO NATALIZUMAB DELAYED USE

    May 1, 2020, 00:00

  • PMH33 VARIATION IN TREATMENT PERSISTENCE BETWEEN ACUTE AND CHRONIC OPIOID USERS RECEIVING BUPRENORPHINE PRODUCTS FOR OPIOID USE DISORDER

    May 1, 2020, 00:00

  • PMS20 COST EFFECTIVENESS OF VIRTUAL REALITY GAME VERSUS CLINIC BASED MCKENZIE EXTENSION THERAPY FOR CHRONIC NON SPECIFIC LOW BACK PAIN

    May 1, 2020, 00:00

  • PDB18 ASSESSMENT OF THE HEALTH CARE UTILIZATION AND ECONOMIC BURDEN ON DIABETES PATIENTS WITH CHRONIC KIDNEY DISEASE IN THE US VETERANS HEALTH ADMINISTRATION POPULATION

    May 1, 2020, 00:00

  • PMH39 ECONOMIC BURDEN ASSOCIATED WITH MAJOR DEPRESSIVE DISORDER, GLOBAL ANXIETY DISORDER, AND POLY-NONCOMMUNICABLE CHRONIC DISEASE (NCCD) COMORBIDITY

    May 1, 2020, 00:00

  • PMU56 IMPACT OF FDA APPROVAL OF NEW AGENTS ON THERAPEUTIC OPTIONS FOR GENETIC VARIANTS IN PEDIATRIC TUMORS

    May 1, 2020, 00:00

  • PIH76 ITCH REPORTED OUTCOME TOOL FOR CAREGIVERS OF PEDIATRIC PATIENTS WITH CHOLESTATIC LIVER DISEASE: AN ANALYSIS OF VALIDATION AND SCORING FROM THE ICONIC MARALIXIBAT STUDY

    May 1, 2020, 00:00

  • Differences in Patient-Reported Outcomes That Are Most Frequently Detected in Randomized Controlled Trials in Patients With Solid Tumors: A Pooled Analysis of 229 Trials

    May 1, 2020, 00:00

  • PDB47 ANNUAL HEALTH INSURANCE TREATMENT COST OF NON-INSULIN-DEPENDENT DIABETES WITH COMPLICATIONS BASED ON ROUTINELY COLLECTED FINANCING DATA

    May 1, 2020, 00:00

  • PCN13 FACTORS THAT MODIFY THE EFFECT OF MONO- OR COMBINATION PD-1/PD-L1 INHIBITOR THERAPIES ON SURVIVAL OUTCOMES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2020, 00:00

  • PDB28 QUALITY ADJUSTED LIFE YEARS (QALYS) IN THE DIABETES PREVENTION PROGRAM (DPP) USING QUALITY OF WELL BEING (QWB) AND SF-6D INSTRUMENTS IN SAME SAMPLE: COMPLETE CASE ANALYSIS

    May 1, 2020, 00:00

  • PMH60 SURVEY OF PATIENT EXPERIENCE AND BURDEN OF ILLNESS IN WOMEN WITH POSTPARTUM DEPRESSION

    May 1, 2020, 00:00

  • PMH34 INTEGRATING COUNTY-LEVEL HEALTH, HUMAN SERVICES, AND CRIMINAL JUSTICE DATA TO PREDICT RISK OF OPIOID OVERDOSE AMONG MEDICAID BENEFICIARIES: A MACHINE LEARNING APPROACH

    May 1, 2020, 00:00

  • PMU41 PREVALENCE AND ASSOCIATED FACTORS TO SUICIDE ATTEMPTS IN LOW-INCOME ADOLESCENTS FROM THE CARIBBEAN REGION OF COLOMBIA

    May 1, 2020, 00:00

  • PMD23 ANALYSIS OF THE COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE REPLACEMENT AS ALTERNATIVE TO SURGICAL AORTIC VALVE REPLACEMENT IN PRIVATE HEALTH INSURANCE IN BRAZIL

    May 1, 2020, 00:00

  • PBI31 MANAGED ENTRY AGREEMENTS FOR ATMPS DESPITE ACCESS ALREADY GRANTED? THE CASE OF GERMANY

    May 1, 2020, 00:00

  • PGI16 BREAKDOWN OF COSTS ATTRIBUTABLE TO CLOSTRIDIOIDES DIFFICILE INFECTION IN THE US: RESULTS FROM A SYSTEMATIC LITERATURE REVIEW

    May 1, 2020, 00:00

  • PDB53 TRENDS IN PRICES OF INSULIN MARKETED IN THE US (1984-2020)

    May 1, 2020, 00:00

  • PIN62 PREVALENCE AND FACTORS ASSOCIATED WITH NEVER-VACCINATED CHILDREN AGED 12-59 MONTHS IN ETHIOPIA. A MULTILEVEL ANALYSIS OF THE INDIVIDUAL AND CONTEXTUAL FACTORS

    May 1, 2020, 00:00

  • PDB95 FACTORS ASSOCIATED WITH MEDICATION NON-ADHERENCE AMONG MEDICARE BENEFICIARIES WITH TYPE 2 DIABETES

    May 1, 2020, 00:00

  • PIN78 CHARACTERIZATION OF UNNECESSARY EMERGENCY DEPARTMENT ENCOUNTERS FOR RABIES POSTEXPOSURE PROPHYLAXIS VACCINATION

    May 1, 2020, 00:00

  • PCN9 TARGETED LITERATURE REVIEW (TLR) OF THE REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG MCRPC PATIENTS IN THE US

    May 1, 2020, 00:00

  • PIH48 DIFFERENTIAL PRESCRIPTION PATTERNS OF DROSPIRENONE-CONTAINING COMBINED ORAL CONTRACEPTIVES IN EUROPE AND NORTH AMERICA - INSIGHTS FROM THE INAS-FOCUS STUDY

    May 1, 2020, 00:00

  • PCV76 IDENTIFYING KNOWLEDGE GAPS IN HEART FAILURE (HF) RESEARCH AMONG WOMEN USING UNSUPERVISED MACHINE LEARNING METHODS

    May 1, 2020, 00:00

  • PMU3 EFFECTIVENESS OF IMPLEMENTATION OF ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN INDIA: EVIDENCE FROM SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2020, 00:00

  • PDB97 DISEASE STATE AWARENESS AND ITS IMPACT ON DISEASE MANAGEMENT IN PATIENTS WITH TYPE 2 DIABETES IN QUETTA, PAKISTAN.

    May 1, 2020, 00:00

  • PIN12 THE COST-EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN CHINESE CITIES

    May 1, 2020, 00:00

  • Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling

    May 1, 2020, 00:00

  • PCN2 PROJECTED LIFETIME CLINICAL VALUE OF A MULTICANCER EARLY DETECTION TEST

    May 1, 2020, 00:00

  • PMH13 ANALYZING TRENDS IN MEDICAL EXPENDITURES ASSOCIATED WITH ALZHEIMER'S DISEASE AMONG U.S. ADULTS WITH DIABETES: 2013-2017

    May 1, 2020, 00:00

  • PMU46 PSYCHOTROPIC POLYPHARMACY AMONG CHILDREN, ADOLESCENTS, AND YOUNG ADULTS TREATED WITH ANTIDEPRESSANTS IN THE UNITED STATES

    May 1, 2020, 00:00

  • Infectious Diseases - Methodological Statistical Research

    May 1, 2020, 00:00

  • PBI11 TRENDS IN LIST PRICES, NET PRICES, AND DISCOUNTS FOR SELF-ADMINISTERED DISEASE-MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS

    May 1, 2020, 00:00

  • PMS6 EFFECTIVENESS AND ACCEPTABILITY OF AMITRIPTYLINE AND FOOD AND DRUG ADMINISTRATION-APPROVED TREATMENTS FOR FIBROMYALGIA: A NETWORK META-ANALYSIS

    May 1, 2020, 00:00

  • PBI32 EVOLUTION OF THE COST OF MEDICINES ACQUIRED BY THE COSTA RICAN SOCIAL SECURITY SYSTEM (CCSS) ACCORDINGLY TO ITS ORIGIN: BIOLOGICAL OR CHEMICAL SYNTHESIS

    May 1, 2020, 00:00

  • Injury Regulatory

    May 1, 2020, 00:00

  • PDB8 STUDY ON STANDARD CRITERIA OF SERUM URIC ACID AND FACTORS OF HIGH URIC ACID IN CHILDREN USING CLAIMS DATABASE IN JAPAN

    May 1, 2020, 00:00

  • Cost-Effectiveness Studies

    May 1, 2020, 00:00

  • Individual's Health - Patient-Centered Research

    May 1, 2020, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Real World Data Information Systems

    May 1, 2020, 00:00

  • PDB89 OBESITY PUBLICATION PATTERNS OVER 20 YEARS: WEIGHING DOWN OBESITY DRUG AVAILABILITY?

    May 1, 2020, 00:00

  • Musculoskeletal Disorders - Health Policy Regulatory

    May 1, 2020, 00:00

  • Drugs Generics - Organizational Practices

    May 1, 2020, 00:00

  • PDB73 EPIDEMIOLOGICAL DISEASE BURDEN OF DIABETIC POLYNEUROPATHY BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00

  • PIH54 PROVISION OF CONTRACEPTIVES AS A MARKER OF POST-PARTUM QUALITY OF CARE AMONG WOMEN ENROLLED IN MEDICAID

    May 1, 2020, 00:00

  • PDB40 COST-EFFECTIVENESS ANALYSIS OF SENSOR-AUGMENTED PUMP IN TYPE 1 DIABETES MELLITUS COMPARED WITH CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN THE RUSSIAN FEDERATION

    May 1, 2020, 00:00

  • Alternative Medicine Nutrition - Medical Technologies

    May 1, 2020, 00:00

  • PDG46 OUTPATIENT OFF-LABEL GABAPENTIN UTILIZATION FROM 2011 TO 2015 AMONG UNITED STATES ADULTS

    May 1, 2020, 00:00

  • PMH10 DETERMINANTS, TRENDS, AND COSTS ASSOCIATED WITH 30-DAY ALL-CAUSE READMISSION IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH SUICIDAL IDEATION USING THE NATIONWIDE READMISSION DATABASE

    May 1, 2020, 00:00

  • PMS45 CLINICAL CHARACTERISTICS AND HEALTH OUTCOMES IN A GROUP OF ELDERLY PATIENTS WITH HIP FRACTURE IN MANIZALES, COLOMBIA.

    May 1, 2020, 00:00

  • PIH47 DEMENTIA SEVERITY AND OPIOID USE IN LONG-TERM CARE NURSING HOME RESIDENTS

    May 1, 2020, 00:00

  • PMS51 GABAPENTIN, OPIOID, AND BENZODIAZEPINE PRESCRIBING IN EARLY CARE OF INDIVIDUALS WITH CHRONIC BACK PAIN: A SECULAR TRENDS ANALYSIS

    May 1, 2020, 00:00

  • PIT4 ECONOMIC BURDEN OF HOSPITALIZATIONS RELATED TO MAJOR AND MEDIUM BURN INJURIES IN BRAZIL

    May 1, 2020, 00:00

  • PMD10 A BUDGET IMPACT AND RETURN ON INVESTMENT ANALYSIS OF INCORPORATING DRUG – ELUTING STENTS INTO A CHINESE HOSPITAL MEDICAL DEVICE FORMULARY — A HOSPITAL PERSPECTIVE

    May 1, 2020, 00:00

  • PMS58 EPIDEMIOLOGICAL DISEASE BURDEN OF INJURIES TO THE ELBOW AND FOREARM BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00

  • AI4 CAN WE DECREASE THE SCREENING BURDEN IN SYSTEMATIC REVIEWS? PERFORMANCE OF TWO NATURAL LANGUAGE PROCESSORS TO EXCLUDE RECORDS

    May 1, 2020, 00:00

  • PCV60 PREVALENCE, RISK FACTORS, AND MANAGEMENT OF UNCONTROLLED HYPERTENSION AMONG DIABETIC PATIENTS: A HOSPITAL-BASED CROSS-SECTIONAL STUDY

    May 1, 2020, 00:00

  • PMU5 PREVALENCE AND ASSOCIATED FACTORS TO PSYCHOTIC SUBSTANCE USE IN LOW-INCOME ADOLESCENTS FROM THE CARIBBEAN REGION OF COLOMBIA

    May 1, 2020, 00:00

  • PIH42 RECURRENT VAGINITIS AND CANDIDIASIS: BURDEN AMONG COMMERCIALLY INSURED WOMEN WITH TYPE II DIABETES IN THE US

    May 1, 2020, 00:00

  • PCN4 ACCURACY OF LIFE YEAR GAIN PREDICTIONS FOR NIVOLUMAB MONOTHERAPY IN THE LONG TERM: AN ANALYSIS ACROSS FOUR INDICATIONS

    May 1, 2020, 00:00

  • PCV75 IDENTIFYING APPROPIATE HOSPITALS FOR PATIENT RECRUITMENT IN CLINICAL TRIALS FOR CANADA USING MACHINE LEARNING ALGORITHMS

    May 1, 2020, 00:00

  • Mental Health - Real World Data Information Systems

    May 1, 2020, 00:00

  • PIN8 HEPATITIS B TREATMENT PATTERNS IN US CLINICAL CARE FOLLOWING TENOFOVIR ALAFENAMIDE (TAF) APPROVAL

    May 1, 2020, 00:00

  • Injury Information Systems

    May 1, 2020, 00:00

  • PIH37 INEQUALITY OF OPPORTUNITY IN MATERNAL HEALTH AMONG ADOLESCENTS

    May 1, 2020, 00:00

  • PMU65 EVALUATION OF HOME HEALTH FOR PATIENTS ELIGIBLE FOR THE POST-ACUTE CARE TRANSFER POLICY

    May 1, 2020, 00:00

  • PDG49 DETERMINANTS OF NON-PHARMACOLOGIC THERAPY, OPIOID, NON-OPIOID/OPIOID COMBINATION, AND NON-OPIOID MEDICATIONS IN OUTPATIENTS WITH NONMALIGNANT CHRONIC PAIN USING RECENT NATIONAL SURVEY

    May 1, 2020, 00:00

  • CC2 COST-EFFECTIVENESS ANALYSIS OF NEWBORN SCREENING AND TREATMENT FOR SPINAL MUSCULAR ATROPHY

    May 1, 2020, 00:00

  • PCV78 ASSESSMENT OF HEALTH LITERACY AND THERAPEUTIC ADHERENCE AMONG PATIENTS WITH HYPERTENSION

    May 1, 2020, 00:00

  • PIN19 A COST EFFECTIVENESS ANALYSIS OF ACTIVE CASE FINDING AND PASSIVE CASE FINDING FOR CASE DETECTION OF TUBERCULOSIS AT KISUGU HC III,KAMPALA UGANDA.

    May 1, 2020, 00:00

  • Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the ISPOR Personalized Precision Medicine Special Interest Group [Editor's Choice]

    May 1, 2020, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Patient-Centered Research

    May 1, 2020, 00:00

  • PIH7 ANNUAL HEALTH INSURANCE TREATMENT COST OF CERVICAL CANCER BASED ON ROUTINELY COLLECTED NATIONWIDE REAL-WORLD FINANCING DATA IN HUNGARY

    May 1, 2020, 00:00

  • PMH12 TRAJECTORY IN HYPNOTIC DRUG USE, SELF-PERCEIVED HEALTH, AND HEALTHCARE EXPENDITURES AMONG PATIENTS DIAGNOSED WITH ANXIETY DISORDERS

    May 1, 2020, 00:00

  • PMU59 GLOBAL OUTCOMES-BASED CONTRACTING TRENDS IN THE US AND EUROPE OVER THE PAST 5 YEARS

    May 1, 2020, 00:00

  • Gastrointestinal Disorders - Methodological Statistical Research

    May 1, 2020, 00:00

  • PMH40 TRENDS IN ATYPICAL ANTIPSYCHOTIC MEDICATION USE IN US ADULTS

    May 1, 2020, 00:00

  • Mental Health - Methodological Statistical Research

    May 1, 2020, 00:00

  • Patient Behavior Studies

    May 1, 2020, 00:00

  • PMH56 FITTING ITEM RESPONSE THEORY MODEL TO DETERMINE THE PSYCHOMETRIC PROPERTIES OF KESSLER PSYCHOLOGICAL DISTRESS SCALE AMONG WOMEN WHO EXCHANGE SEX

    May 1, 2020, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Patient-Centered Research

    May 1, 2020, 00:00

  • Individual's Health - Real World Data Information Systems

    May 1, 2020, 00:00

  • Multiple Diseases - Epidemiology Public Health

    May 1, 2020, 00:00

  • PDB4 SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF THE EFFECT OF NALTREXONE/ BUPROPION COMPARED WITH OTHER ANTI-OBESITY DRUGS IN OVERWEIGHT AND OBESE PATIENTS

    May 1, 2020, 00:00

  • PIN76 CHARACTERISTICS OF PATIENTS WITH CHRONIC HEPATITIS C TREATED UNDER A NEW STANDARD OF CARE

    May 1, 2020, 00:00

  • PDB68 CHARACTERISTICS OF PATIENTS WITH SEVERE HYPOGLYCEMIA AMONG PATIENTS WITH DIABETES USING INSULIN IN COMMERCIALLY INSURED, MEDICARE, AND MEDICAID POPULATION

    May 1, 2020, 00:00

  • PIH70 FORMATIVE RESEARCH TO DEVELOP A CLINICAL TRIAL DECISION AID THAT INTEGRATES QUANTITATIVE PATIENT PREFERENCE DATA

    May 1, 2020, 00:00

  • PIN7 REAL-WORLD EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS (DAA) IN YOUNG ADULT (18-25) AND ELDERLY (80+) POPULATIONS WITH HEPATITIS C (HCV)

    May 1, 2020, 00:00

  • PDG75 PREVALENCE AND FACTORS ASSOCIATED WITH ANTIEPILEPTIC DRUG USE IN NURSING HOME RESIDENTS WITH PAIN

    May 1, 2020, 00:00

  • PIH21 EFFICACY AND SAFETY OF IMRECOXIB, CELECOXIB AND DICLOFENAC IN PATIENTS WITH OSTEOARTHRITIS: A NETWORK META-ANALYSIS

    May 1, 2020, 00:00

  • PIN21 ESTABLISH A PHARMACEUTICAL CARE MODE FOR THERAPEUTIC DRUG MONITORING OF VANCOMYCIN AND EVALUATE ITS EFFECTIVENESS AND ECONOMICS

    May 1, 2020, 00:00

  • PAM11 DEVELOPMENT AND EVALUATION OF THE BLOOD DEFICIENCY QUESTIONNAIRE (BDQ)

    May 1, 2020, 00:00

  • PIH29 ECONOMIC BURDEN OF ENDOMETRIOSIS: A SYSTEMATIC LITERATURE REVIEW

    May 1, 2020, 00:00

  • PIH58 GEOGRAPHICAL DISPARITIES IN NON-UTILIZATION OF HEALTH FACILITY DELIVERY AND POSTNATAL SERVICES IN GHANA

    May 1, 2020, 00:00

  • PDB50 ANNUAL HEALTH INSURANCE TREATMENT COST OF DIABETIC POLYNEUROPATHY BASED ON ROUTINELY COLLECTED FINANCING DATA

    May 1, 2020, 00:00

  • PDG48 PRESCRIBING PRACTICES FOR HYPERLIPIDEMIA AMONG U.S. AMBULATORY PATIENTS

    May 1, 2020, 00:00

  • PMU60 DO COMPANIES SEQUENCE THE LAUNCH OF INDICATIONS FOR MULTI-INDICATION PRODUCTS?

    May 1, 2020, 00:00

  • PDG14 BUDGET IMPACT ANALYSIS OF GIPAP AND VPAP TERMINATION WITHIN THE NEXT 5 YEARS IN VIETNAM

    May 1, 2020, 00:00

  • PMH11 LONG-TERM MEDICATION-ASSISTED TREATMENT OF OPIOID USE DISORDER IN THE UNITED STATES: A COST-UTILITY ANALYSIS

    May 1, 2020, 00:00

  • AI2 PREDICTORS OF PARKINSON DISEASE IN A MEDICARE POPULATION: AN APPLICATION OF MACHINE LEARNING IN EARLY DISEASE DETECTION

    May 1, 2020, 00:00

  • Cardiovascular Disorders - Real World Data Information Systems

    May 1, 2020, 00:00

  • PDG41 CLOSURE OF THE PART D COVERAGE GAP AND OUT-OF-POCKET COSTS FOR RHEUMATOID ARTHRITIS BIOLOGICS IN MEDICARE PART D

    May 1, 2020, 00:00

  • PGI26 THE COST-EFFECTIVENESS OF PHARMACOLOGIC VS SURGICAL INTERVENTION FOR PATIENTS HOSPITALIZED WITH ACUTE SEVERE ULCERATIVE COLITIS IN THE UNITED STATES

    May 1, 2020, 00:00

  • Musculoskeletal Disorders - Real World Data Information Systems

    May 1, 2020, 00:00

  • PIN87 PATIENT ENGAGEMENT IN HIV CARE MANAGEMENT: BEHAVIOR ECONOMICS OF ART ADHERENCE AND ESTABLISHING CARE VISITS

    May 1, 2020, 00:00

  • PGI36 ESTIMATION OF THE MINIMAL IMPORTANT DIFFERENCES IN EUROQOL-5 DIMENSIONS (EQ-5D) FOR PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: ANALYSIS FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF BUDESONIDE ORAL SUSPENSION

    May 1, 2020, 00:00

  • PMU44 PREVALENCE OF MULTIMORBIDITY AMONG ASIAN INDIANS, CHINESE, AND NON-HISPANIC WHITES IN THE UNITED STATES

    May 1, 2020, 00:00

  • PMD32 RISK AND OUTCOMES FOLLOWING APPLICATION OF MULTI-PLANAR RING FIXATION SYSTEMS - A TWELVE YEAR REVIEW FROM A US CLAIMS DATABASE ANALYSIS

    May 1, 2020, 00:00

  • Competing Views on the English EQ-5D-5L Valuation Set [Editor's Choice]

    May 1, 2020, 00:00

  • PMS40 REAL-WORLD TREATMENT PATTERNS AND ECONOMIC BURDEN OF ROTATOR CUFF TEAR PATIENTS IN THE US

    May 1, 2020, 00:00

  • Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing–Based Tests: Challenges, Opportunities, and Potential Solutions

    May 1, 2020, 00:00

  • PIH31 INVERSE RELATIONSHIP BETWEEN ANEMIA IN THE THIRD TRIMESTER OF PREGNANCY AND LOW BIRTH WEIGHT IN A REFERENCE MATERNITY UNIT OF A CARRIBEAN REGION OF COLOMBIA

    May 1, 2020, 00:00

  • PCV57 THE BURDEN OF HEART FAILURE IN NORTH AMERICA AND WESTERN EUROPE

    May 1, 2020, 00:00

  • PMH46 GEOGRAPHIC VARIATION IN TREATMENT ADMISSIONS FOR OPIOID USE DISORDER IN CINCINNATI COMPARED TO THE UNITED STATES

    May 1, 2020, 00:00

  • PIN69 NOW OR LATER: THE COST BURDEN OF HCV INFECTION VS. TREATMENT FOR MEDICARE AND MEDICAID POPULATIONS

    May 1, 2020, 00:00

  • Medical Devices - Health Policy Regulatory

    May 1, 2020, 00:00

  • Infectious Diseases - Real World Data Information Systems

    May 1, 2020, 00:00

  • PMS7 THE ROLE OF SPECIALIZED PRO-RESOLVING LIPID MEDIATORS IN THE TREATMENT OF INFLAMMATION CAUSED BY EXERCISING: A SYSTEMATIC REVIEW

    May 1, 2020, 00:00

  • PGI35 REAL-WORLD MEDICATION USE AND COST OF ILLNESS IN IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN THE CHINESE SETTING

    May 1, 2020, 00:00

  • PIN20 SOCIETAL PRODUCTIVITY GAINS FROM NEW THERAPIES IN HEPATITIS C

    May 1, 2020, 00:00

  • PIH43 SEXUAL BEHAVIOR, USE OF CONTRACEPTIVE METHODS AND PREGNANCY IN YOUNG PEOPLE FROM A POPULATION AFFILIATED IN A HEALTH INSURER COMPANY IN COLOMBIA 2018

    May 1, 2020, 00:00

  • PMU11 ASSOCIATION BETWEEN DEPRESSION AND HEALTHCARE EXPENDITURES AMONG STROKE SURVIVORS

    May 1, 2020, 00:00

  • PMU6 EFFECTIVENESS OF A NATIVE TYPE I COLLAGEN MATRIX PLUS POLYHEXAMETHYLENE BIGUANIDE ANTIMICROBIAL (PHMB) FOR THE TREATMENT OF CUTANEOUS WOUNDS IN A REAL WORLD SETTING

    May 1, 2020, 00:00

  • PDB32 COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VS. CANAGLIFLOZIN 300 MG IN PATIENTS WITH TYPE 2 DIABETES IN A CANADIAN SETTING

    May 1, 2020, 00:00

  • PMS65 A VISUAL ANALYTICAL APPROACH TO UNDERSTANDING TREATMENT PATTERNS AMONG TREATMENT-NAÏVE RHEUMATOID ARTHRITIS PATIENTS WITH BIOLOGIC USE IN THE US VETERANS HEALTH ADMINISTRATION DATABASE

    May 1, 2020, 00:00

  • PMU39 COOKING AT HOME CAN SAVE MONEY, REGARDLESS OF FOOD PRICE: A MULTILEVEL ANALYSIS OF MEALS PREPARED AWAY FROM THE HOME ON DIET MEASURES AND FOOD EXPENDITURES

    May 1, 2020, 00:00

  • PMH63 HUMANISTIC BURDEN ASSOCIATED WITH MAJOR DEPRESSIVE DISORDER AND GLOBAL ANXIETY DISORDER AMONG ADULTS WITH NON-COMMUNICABLE DISEASES (NCCDS) IN THE UNITED STATES

    May 1, 2020, 00:00

  • PIH35 LONG-TERM PRESCRIPTION OPIOID USE AMONG OLDER ADULTS IN THE UNITED STATES

    May 1, 2020, 00:00

  • PMS52 EPIDEMIOLOGY OF DERMATITIS ATOPIC IN AMERICA: SYSTEMATIC REVIEW

    May 1, 2020, 00:00

  • PDG47 OUTPATIENT OPIOID PRESCRIBING AMONG PATIENTS WITH RHEUMATOID ARTHRITIS: ANALYSIS OF NATIONAL AMBULATORY MEDICAL CARE SURVEY, 2011-2016

    May 1, 2020, 00:00

  • PCN15 EFFICACY, EFFECTIVENESS, AND SAFETY OF FRONTLINE TREATMENTS FOR PERIPHERAL T-CELL LYMPHOMA

    May 1, 2020, 00:00

  • PGI23 TREATMENT COST ANALYSIS FOR PATIENTS IN THE UNITED STATES WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE AN INADEQUATE RESPONSE OR WHO ARE INTOLERANT TO TNF BLOCKERS

    May 1, 2020, 00:00

  • Editorial Board

    Apr 21, 2020, 08:38

  • Public Attitudes on Lung Cancer Screening and Radiation Risk: A Best-Worst Experiment

    Apr 1, 2020, 00:00

  • Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications

    Apr 1, 2020, 00:00

  • A Systematic Review of the Feasibility and Psychometric Properties of the ICEpop CAPability Measure for Adults and Its Use So Far in Economic Evaluation

    Apr 1, 2020, 00:00

  • Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France

    Apr 1, 2020, 00:00

  • Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report [Editor's Choice]

    Apr 1, 2020, 00:00

  • Table of Contents

    Apr 1, 2020, 00:00

  • Ranking the Criteria Used in the Appraisal of Drugs for Reimbursement: A Stated Preferences Elicitation With Health Technology Assessment Stakeholders Across Jurisdictional Contexts

    Apr 1, 2020, 00:00

  • Are Value-Based Arrangements the Answer We’ve Been Waiting for?

    Apr 1, 2020, 00:00

  • Using the Choice Sequence in Time Trade-Off as Discrete Choices: Do the Two Stories Match? [Editor's Choice]

    Apr 1, 2020, 00:00

  • Is There a Future for Value-Based Contracting? [Editor's Choice]

    Apr 1, 2020, 00:00

  • Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users

    Apr 1, 2020, 00:00

  • Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim

    Apr 1, 2020, 00:00

  • Copyright/Subscription

    Apr 1, 2020, 00:00

  • Reporting Quality of Discrete Event Simulations in Healthcare—Results From a Generic Reporting Checklist

    Apr 1, 2020, 00:00

  • Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead

    Apr 1, 2020, 00:00

  • Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma

    Apr 1, 2020, 00:00

  • Managed Entry Agreements: Policy Analysis From the European Perspective [Editor's Choice]

    Apr 1, 2020, 00:00

  • Editorial Board

    Mar 18, 2020, 10:02

  • Author's Reply

    Mar 1, 2020, 00:00

  • Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis

    Mar 1, 2020, 00:00

  • Socioeconomic Status of Newborns and Hospital Efficiency: Implications for Hospital Payment Methods

    Mar 1, 2020, 00:00

  • How Are Debriefing Questions Used in Health Discrete Choice Experiments? An Online Survey

    Mar 1, 2020, 00:00

  • Mapping WOMAC Onto the EQ-5D-5L Utility Index in Patients With Hip or Knee Osteoarthritis

    Mar 1, 2020, 00:00

  • Are Current Reporting Standards Used to Describe Health State Utilities in Cost-Effectiveness Models Satisfactory?

    Mar 1, 2020, 00:00

  • Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting [Editor's Choice]

    Mar 1, 2020, 00:00

  • Moving Beyond the Tip of the Iceberg to Incorporate Patients’ Perspectives and Outcomes in the Medical Device Regulatory Process

    Mar 1, 2020, 00:00

  • Cost-Effectiveness Analysis of Screening for Persistent Hepatitis E Virus Infection in Solid Organ Transplant Patients in the United Kingdom: A Model-Based Economic Evaluation

    Mar 1, 2020, 00:00

  • Table of Contents

    Mar 1, 2020, 00:00

  • A Step Closer to Better Research Prioritization? The ISPOR Value of Information Task Force Reports

    Mar 1, 2020, 00:00

  • Measuring Quality-Adjusted Life-Years When Health Fluctuates

    Mar 1, 2020, 00:00

  • Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs [Editor's Choice]

    Mar 1, 2020, 00:00

  • Psychometric Analysis of the Abdominal Score From the Diary for Irritable Bowel Syndrome Symptoms–Constipation Using Phase IIb Clinical Trial Data

    Mar 1, 2020, 00:00

  • Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force [Editor's Choice]

    Mar 1, 2020, 00:00

  • Integrating the Voice of the Patient Into the Medical Device Regulatory Process Using Patient Preference Information

    Mar 1, 2020, 00:00

  • Letter to the Editor: Methods for Measuring Multiple Medication Adherence: A Systematic Review

    Mar 1, 2020, 00:00

  • Subscription Page

    Mar 1, 2020, 00:00

  • Computing PROPr Utility Scores for PROMIS® Profile Instruments

    Mar 1, 2020, 00:00

  • Economic Evaluation of User-Fee Exemption Policies for Maternal Healthcare in Burkina Faso: Evidence From a Cost-Effectiveness Analysis

    Mar 1, 2020, 00:00

  • Exploratory Factor Analysis of a Patient-Centered Cancer Care Measure to Support Improved Assessment of Patients’ Experiences

    Mar 1, 2020, 00:00

  • Editorial Board

    Feb 27, 2020, 10:34

  • Health-Related Quality of Life in Children With Low Language or Congenital Hearing Loss, as Measured by the PedsQL and Health Utility Index Mark 3

    Feb 1, 2020, 00:00

  • “Stick or Twist?” Negotiating Price and Data in an Era of Conditional Approval

    Feb 1, 2020, 00:00

  • Copyright/Subscription

    Feb 1, 2020, 00:00

  • Why Reinvent the Wheel? Use or Modification of Existing Clinical Outcome Assessment Tools in Medical Product Development [Editor's Choice]

    Feb 1, 2020, 00:00

  • Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus

    Feb 1, 2020, 00:00

  • Value-Based Pharmaceutical Contracts: Value for Whom?

    Feb 1, 2020, 00:00

  • Evaluation of Efficacy Endpoints for a Phase IIb Study of a Respiratory Syncytial Virus Vaccine in Older Adults Using Patient-Reported Outcomes With Laboratory Confirmation

    Feb 1, 2020, 00:00

  • Supporting the Development of Evidence-Informed Policy Options: An Economic Evaluation of Hypertension Management in Ghana

    Feb 1, 2020, 00:00

  • Comparison of Different Case-Crossover Variants in Handling Exposure-Time Trend or Persistent-User Bias: Using Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure as an Example

    Feb 1, 2020, 00:00

  • A Head-On Ordinal Comparison of the Composite Time Trade-Off and the Better-Than-Dead Method

    Feb 1, 2020, 00:00

  • Table of Contents

    Feb 1, 2020, 00:00

  • Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force

    Feb 1, 2020, 00:00

  • Optimal Design of Population-Level Financial Incentives of Influenza Vaccination for the Elderly

    Feb 1, 2020, 00:00

  • Clinical Effectiveness of Decision Support for Prescribing Opioids for Chronic Noncancer Pain: A Prospective Cohort Study

    Feb 1, 2020, 00:00

  • Quebec Health-Related Quality-of-Life Population Norms Using the EQ-5D-5L: Decomposition by Sociodemographic Data and Health Problems [Editor's Choice]

    Feb 1, 2020, 00:00

  • Effects of Lean Healthcare on Patient Flow: A Systematic Review

    Feb 1, 2020, 00:00

  • What Difference Does It Make? A Comparison of Health State Preferences Elicited From the General Population and From People With Multiple Sclerosis

    Feb 1, 2020, 00:00

  • To HTA or Not to HTA: Identifying the Factors Influencing the Rapid Review Outcome in Ireland

    Feb 1, 2020, 00:00

  • Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions [Editor's Choice]

    Feb 1, 2020, 00:00

  • Author's Reply

    Feb 1, 2020, 00:00

  • Editorial Board

    Jan 15, 2020, 08:20

  • Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review

    Jan 1, 2020, 00:00

  • Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review

    Jan 1, 2020, 00:00

  • Copyright/Subscription

    Jan 1, 2020, 00:00

  • Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical Analysis [Editor's Choice]

    Jan 1, 2020, 00:00

  • Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention

    Jan 1, 2020, 00:00

  • Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations

    Jan 1, 2020, 00:00

  • Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis [Editor's Choice]

    Jan 1, 2020, 00:00

  • Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System

    Jan 1, 2020, 00:00

  • Role of Culture, Values, and Politics in the Implementation of Health Technology Assessment in India: A Commentary

    Jan 1, 2020, 00:00

  • A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C

    Jan 1, 2020, 00:00

  • HTA Around the World: Broadening Our Understanding of Cross-Country Differences [Editor's Choice]

    Jan 1, 2020, 00:00

  • Costs and Benefits of Alternative Strategies to Control the Spread of Livestock-Acquired Methicillin-Resistant Staphylococcus Aureus From Pig Production

    Jan 1, 2020, 00:00

  • Increasing the Legitimacy of Tough Choices in Healthcare Reimbursement: Approach and Results of a Citizen Forum in The Netherlands

    Jan 1, 2020, 00:00

  • Table of Contents

    Jan 1, 2020, 00:00

  • Development of System Performance Indicators for Adolescent and Young Adult Cancer Care and Control in Canada

    Jan 1, 2020, 00:00

  • Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?

    Jan 1, 2020, 00:00

  • Concepts and Instruments for Patient-Reported Outcome Assessment in Celiac Disease: Literature Review and Experts’ Perspectives

    Jan 1, 2020, 00:00

  • The Emerging Social Science Literature on Health Technology Assessment: A Narrative Review

    Jan 1, 2020, 00:00

  • Disclosure Information

    Dec 17, 2019, 09:25

  • Editorial Board

    Dec 3, 2019, 08:15

  • Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis

    Dec 1, 2019, 00:00

  • Table of Contents

    Dec 1, 2019, 00:00

  • Excess Costs and Economic Burden of Obesity-Related Cancers in the United States [Editor's Choice]

    Dec 1, 2019, 00:00

  • Propensity Score Weighting Using Overlap Weights: A New Method Applied to Regorafenib Clinical Data and a Cost-Effectiveness Analysis

    Dec 1, 2019, 00:00

  • Community-Based Services by Pharmacists: A Systematic Review of Cost-Utility Analyses

    Dec 1, 2019, 00:00

  • How Should We Capture Health State Utility in Dementia? Comparisons of DEMQOL-Proxy-U and of Self- and Proxy-Completed EQ-5D-5L [Editor's Choice]

    Dec 1, 2019, 00:00

  • Equity Weights for Priority Setting in Healthcare: Severity, Age, or Both?

    Dec 1, 2019, 00:00

  • Measuring Productivity Costs in Patients With Musculoskeletal Disorders: Measurement Properties of the Institute for Medical Technology Assessment Productivity Cost Questionnaire

    Dec 1, 2019, 00:00

  • Cost-Effectiveness Analysis for Influenza Vaccination Coverage and Timing in Tropical and Subtropical Climate Settings: A Modeling Study

    Dec 1, 2019, 00:00

  • Cost-Effectiveness of Drug-Eluting Stents in Elderly Patients With Coronary Artery Disease: The SENIOR Trial

    Dec 1, 2019, 00:00

  • Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model

    Dec 1, 2019, 00:00

  • Copyright/Subscription

    Dec 1, 2019, 00:00

  • Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017

    Dec 1, 2019, 00:00

  • Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments? [Editor's Choice]

    Dec 1, 2019, 00:00

  • Carer Social Care-Related Quality of Life Outcomes: Estimating English Preference Weights for the Adult Social Care Outcomes Toolkit for Carers

    Dec 1, 2019, 00:00

  • Cost-Effectiveness of Antihypertensive Therapy in Patients Older Than 80 Years: Cohort Study and Markov Model

    Dec 1, 2019, 00:00

  • Editorial Board

    Nov 13, 2019, 17:52

  • Cardiovascular Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PNS273 ICER: SIMILARITIES AND DIFFERENCES BETWEEN UK (ENGLAND) AND USA COST-EFFECTIVENESS WATCHDOGS

    Nov 1, 2019, 00:00

  • PMU29 ECONOMIC EVALUATION FOR THE TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURES INFECTIONS (ABSSSI) FROM THE NATIONAL PAYER PERSPECTIVE: INTRODUCTION OF A NEW TREATMENT INTO THE PATIENT JOURNEY. SIMULATION IN 3 EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PIH61 VALIDATION OF THE STUDY MEDICATION SATISFACTION QUESTIONNAIRE (SMSQ). A MEASURE OF MEDICATION SATISFACTION DESIGNED FOR INDIVIDUALS TAKING PRE-EXPOSURE PROPHYLAXIS (PREP) MEDICATION FOR HIV

    Nov 1, 2019, 00:00

  • PBI67 METHODOLOGICAL DESIGN OF ADVANCED INTERVENTIONAL TRIALS FOR GENE THERAPIES

    Nov 1, 2019, 00:00

  • PMS52 CLINICAL GUIDELINE DEVELOPMENT FOR THE MANAGEMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN IN PRIMARY CARE

    Nov 1, 2019, 00:00

  • PCN370 IMPROVING PATIENT ACCESS TO INNOVATIVE MEDICATIONS WHILE PROTECTING PUBLIC BUDGETS SUSTAINABILITY: AN ALTERNATIVE GO TO MARKET AND PRICING FRAMEWORK TO ENABLE VALUE CO-CREATION BETWEEN PHARMAS AND PAYERS

    Nov 1, 2019, 00:00

  • PMU4 WHAT IS A GOOD OR BAD NUMBER NEED TO TREAT (NNT) VALUE? A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PDG79 WAS THE EVIDENCE BASE FOR YESCARTA AND KYMRIAH SUFFICIENT TO JUSTIFY THEIR COST AND SECURE PATIENT ACCESS ACROSS 5 MARKETS?

    Nov 1, 2019, 00:00

  • PDG74 AN ANALYSIS OF RESTRICTED RECOMMENDATIONS BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Nov 1, 2019, 00:00

  • PCV152 SELF-ASSESSED FUNCTIONAL CLASS, QUALITY OF LIFE AND HEALTHCARE RESOURCE CONSUMPTION IN PORTUGUESE HEART FAILURE PATIENTS: AN ANALYSIS OF THE PRIME STUDY

    Nov 1, 2019, 00:00

  • PCN80 REAL-WORLD HEALTHCARE COSTS IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER IN ITALY

    Nov 1, 2019, 00:00

  • PCN280 CHARACTERIZING THE CONTINUED RELEVANCE OF IRP IN ITALY: A SIMULATION ANALYSIS OF TOP PRESCRIBED MOLECULES IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PCV104 A SYSTEMATIC REVIEW OF ORGANISATIONAL AND SERVICE SPECIFICATION RECOMMENDATIONS FOR CENTRES PROVIDING PERCUTANEOUS CORONARY INTERVENTIONS

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PNS182 SYSTEMIC ADMINISTRATION OF GLUCOCORTICOIDS IN GUIZHOU PROVINCE, CHINA: A SURVEY AMONG HOSPITAL PHARMACIES.

    Nov 1, 2019, 00:00

  • PCN403 IDENTIFYING KEY CRITERIA FOR HEALTH TECHNOLOGY ASSESSMENT FOR ADJUVANT TREATMENT OF EARLY BREAST CANCER IN BRAZIL: A MCDA APPROACH

    Nov 1, 2019, 00:00

  • PIH40 ASSESSING HEALTH DISPARITY IN THE ELDERLY POPULATION WITH DIFFERENT ECONOMIC STATUS IN SOUTH KOREA: FOCUSING ON HIP FRACTURE

    Nov 1, 2019, 00:00

  • PCN43 NEW CERVICAL CANCER SCREENING POLICY IN GERMANY - WHAT IS THE IMPACT ON THE BENEFIT-HARM BALANCE?

    Nov 1, 2019, 00:00

  • PIH56 PLACE OF COMPLEMENTARY MEDICINES AND OPPORTUNITIES IN THE MANAGEMENT OF GYNECOLOGICAL CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PCN266 PATIENT, DISEASE CHARACTERISTICS AND TREATMENT PATTERNS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN GREECE: RESULTS FROM ANALYSIS OF A GREEK CLL-DATABASE

    Nov 1, 2019, 00:00

  • PCN178 MODELLING THE BUDGET IMPACT OF INTRODUCING 3D MAMMOGRAPHY FOR BREAST CANCER SCREENING IN GERMANY

    Nov 1, 2019, 00:00

  • Alternative Medicine Nutrition - Economic Evaluation

    Nov 1, 2019, 00:00

  • PIN130 COST-EFFECTIVENESS ANALYSIS OF CEFTAZIDIME/AVIBACTAM FOR THE TREATMENT OF ADULTS WITH COMPLICATED URINARY TRACT INFECTIONS IN BULGARIA

    Nov 1, 2019, 00:00

  • PCN378 PHARMACOECONOMIC ANALYSIS OF ATEZOLIZUMAB PLUS NAB-PACLITAXEL IN THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER

    Nov 1, 2019, 00:00

  • PDB57 COST SAVINGS ASSOCIATED WITH PREMIX VERSUS BASAL-BOLUS REGIMEN IN ALGERIAN PATIENTS WITH TYPE 2 DIABETES INSUFFICIENTLY CONTROLLED UNDER BASAL INSULIN REGIMEN

    Nov 1, 2019, 00:00

  • PBI24 SECUKINUMAB VS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM AN ALGERIAN PERSPECTIVE

    Nov 1, 2019, 00:00

  • PNS347 SCIENTIFIC OUTCOME OF ISPOR CONFERENCES: AN ANALYSIS OF 44,390 ABSTRACTS PRESENTED AT 38 ISPOR CONFERENCES BETWEEN 2002-2018

    Nov 1, 2019, 00:00

  • PCN424 NETWORK META-ANALYSIS FOR IMMUNE ONCOLOGY TRIALS USING SPLINES

    Nov 1, 2019, 00:00

  • PCV92 ANALYSING DATA OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ACCORDING TO PROGRESSIVITY LEVELS IN HUNGARY (COMPARISON OF 2013 AND 2018)

    Nov 1, 2019, 00:00

  • PIN115 ANALYZING SOCIO-ECONOMIC INEQUALITY IN CHILDHOOD IMMUNIZATION COVERAGE IN ETHIOPIA

    Nov 1, 2019, 00:00

  • PUK12 ANALYSIS OF COST AND CONSEQUENCES RELATED TO THE PERSISTENCE OF MIRABEGRON AND ANTIMUSCARINIC TREATMENTS AND THEIR IMPACT ON QUALITY OF LIFE IN PATIENTS AGED ≥ 65 YEARS WITH OVERACTIVE BLADDER IN SPAIN

    Nov 1, 2019, 00:00

  • Multiple Diseases - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PCN103 A COMPARISON OF PARTITIONED-SURVIVAL AND STATE TRANSITION MODELLING APPROACHES - FINDINGS FROM A CASE STUDY IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PDB15 THE COST OF HYPOGLYCAEMIA IN TYPE 2 DIABETES MELLITUS IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PMS34 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE WRIST AND HAND IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PRO120 EVOLUTION OF OBCS NECESSARY TO ACTIVATE VALUE WITHIN STEM CELL RARE DISEASES

    Nov 1, 2019, 00:00

  • PDB52 ECONOMIC BURDEN ASSOCIATED WITH DIABETIC RETINOPATHY: EVIDENCE FROM A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN15 PROPHYLAXIS FOR BICALUTAMIDE-INDUCED GYNECOMASTIA: A NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PMU45 PREVALENCE VS. TREATMENT COST: ANALYSIS OF DRUGS FOR RARE DISEASE IN ITALY

    Nov 1, 2019, 00:00

  • PMU87 REVIEW OF ORPHAN TREATMENTS ASSESSED BY NICE AND THE SMC IN THE UK.

    Nov 1, 2019, 00:00

  • PNS20 RECENT ADVANCES IN THE EUROPEAN CROSS-BORDER COLLABORATIONS IN JOINT DRUG PROCUREMENT LANDSCAPE

    Nov 1, 2019, 00:00

  • PRS27 THE USE OF ECONOMICAL TRADITIONAL HERBAL MEDICINAL PLANTS AMONG DIFFERENT COMMUNITIES OF BALOCHISTAN AGAINST ASTHMA

    Nov 1, 2019, 00:00

  • PND9 UPDATED META-ANALYSIS OF THE EFFICACY OF ADJUVANT TREATMENT TO LEVODOPA IN PARKINSON'S DISEASE

    Nov 1, 2019, 00:00

  • PBI89 PHARMACOUTILIZATION OF BIOLOGICAL DRUGS IN PATIENTS AFFECTED BY PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS IN AN ITALIAN REAL-WORLD SETTING

    Nov 1, 2019, 00:00

  • PMS78 CANADIAN REAL-WORLD EVIDENCE ON EPIDEMIOLOGY, OUTCOMES AND ECONOMICS OF MODERATE-TO-SEVERE OSTEOARTHRITIS: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PBI71 EXPLORING UNCERTAINTIES AND SOLUTIONS ALLOWING PATIENT ACCESS TO CAR T-CELL THERAPIES: LEARNING TODAY HOW TO IMPROVE TOMORROW

    Nov 1, 2019, 00:00

  • PCN141 USE OF COST-EFFECTIVENESS AFFORDABILITY CURVES IN EVALUATING CANCER DRUGS IN ENGLAND

    Nov 1, 2019, 00:00

  • PMU53 THE INCENTIVE FINANCIAL FRAMEWORK REGARDING FRENCH HOSPITAL PRESCRIPTION OF BIOSIMILAR MEDICINES WHEN DELIVERED IN RETAIL PHARMACY: IMPACT ANALYSIS OF ARTICLE 51 EXPERIMENTATION FOR 2018

    Nov 1, 2019, 00:00

  • PCV50 COST-EFFECTIVENESS OF TARGETED SCREENING USING A MACHINE LEARNING RISK PREDICTION TOOL FOR THE IDENTIFICATION OF PATIENTS WITH ATRIAL FIBRILLATION

    Nov 1, 2019, 00:00

  • PNS199 BARRIERS TO THE USE OF HEALTH SERVICES AMONG THE ELDERLY POPULATION OF A RURAL REGIONAL UNITY IN GREECE: A CROSS-SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PNS291 ANALYSIS OF RECALLS OF MEDICAL DEVICES FROM 2009 TO 2018 BY RISK CLASS AND DEVICE CATEGORY BASED ON ITALIAN DATA

    Nov 1, 2019, 00:00

  • PCN487 COST OF PROSTATE CANCER AND QUALITY OF LIFE IN EGYPT - A PATIENT PERSPECTIVE STUDY

    Nov 1, 2019, 00:00

  • PGI10 COST-UTILITY ANALYSIS OF USTEKINUMAB VS VEDOLIZUMAB IN CROHN DISEASE IN ITALY

    Nov 1, 2019, 00:00

  • PGI27 THE BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN THE EU5 COUNTRIES

    Nov 1, 2019, 00:00

  • PRO132 DISEASE BURDEN OF X-LINKED HYPOPHOSPHATEMIA

    Nov 1, 2019, 00:00

  • PCV51 COST-EFFECTIVENESS OF RIVAROXABAN IN THE TREATMENT OF PATIENTS WITH CHRONIC CAD OR PAD IN THE UK

    Nov 1, 2019, 00:00

  • PCN68 BRENTUXIMAB VEDOTIN FOR CONSOLIDATION THERAPY AFTER ASCT IN CD30+ HODGKIN'S LYMPHOMA: A SUSTAINABLE PHARMACEUTICAL EXPENDITURE FOR THE ITALIAN NATIONAL HEALTH SERVICE

    Nov 1, 2019, 00:00

  • PNS418 WHEN THE COMPARATOR HAS A CONFIDENTIAL PRICE - A REVIEW OF RECENT CASES IN SWEDEN

    Nov 1, 2019, 00:00

  • PNS35 MULTI-NATIONAL NORDIC PHARMACOEPIDEMIOLOGIC STUDIES: OPPORTUNITIES AND CHALLENGES

    Nov 1, 2019, 00:00

  • PSU34 COMPLICATIONS AND REIMBURSEMENT AMONG PATIENTS WITH HAMMERTOE SURGERY: A MEDICARE SUPPLEMENTAL DATABASE STUDY WITH TWO YEARS FOLLOW-UP

    Nov 1, 2019, 00:00

  • PCN244 BUDGETARY IMPACT OF VENETOCLAX WITH RITUXIMAB VERSUS IBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00

  • PCV44 COST ANALYSIS OF THE INTRODUCTION OF A SINGLE-PILL COMBINATION OF ROSUVASTATIN AND EZETIMIBE IN THE GREEK SETTING

    Nov 1, 2019, 00:00

  • PDG18 COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT IN TREATING NAMD IN CHINA

    Nov 1, 2019, 00:00

  • PMU68 THE ROLE OF OUTCOMES-BASED MODELS FOR THE REIMBURSEMENT OF MEDICINES IN THE UK NATIONAL HEALTH SERVICE

    Nov 1, 2019, 00:00

  • PDB123 CURRENT STATUS AND USE OF RESOURCES OF LYSOSOMAL STORAGE DISEASES: ANALYSIS OF A SPANISH CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • Drugs Public Health

    Nov 1, 2019, 00:00

  • PNS290 EVIDENCE-BASED VALUE FRAMEWORK FOR THE EVALUATION OF CLINICAL PHARMACY SERVICES

    Nov 1, 2019, 00:00

  • PIN44 COST-EFFECTIVENESS OF QUADRIVALENT VERSUS TRIVALENT INFLUENZA VACCINATION IN THE DUTCH NATIONAL INFLUENZA PREVENTION PROGRAM

    Nov 1, 2019, 00:00

  • PRS48 UNLOCKING THE ACCESS CHALLENGES TO COPD

    Nov 1, 2019, 00:00

  • PDB120 COSTS AND RESOURCE USE ASSOCIATED WITH SEVERE HYPOGLYCEMIC EVENTS IN PATIENTS WITH DIABETES IN IRAN

    Nov 1, 2019, 00:00

  • PMH13 SYSTEMATIC REVIEW OF UTILITY VALUES USED IN THE PHARMACOECONOMIC EVALUATIONS FOR SCHIZOPHRENIA: IMPLICATIONS ON COST-EFFECTIVENESS RESULTS

    Nov 1, 2019, 00:00

  • PNS109 PERCEPTIONS AND PRACTICES OF SELF- MEDICATION IN AN INDIAN URBAN COMMUNITY

    Nov 1, 2019, 00:00

  • PNS371 EVALUATING QUALITY OF PRIMARY HEALTH CARE (PHC) SERVICES FROM THE PATIENTS' PERSPECTIVE IN GREECE

    Nov 1, 2019, 00:00

  • PNS255 USING PEST ANALYSIS TO CREATE AN HTA-INFORMED HEALTH CARE DECISION-MAKING ECOSYSTEM IN UKRAINE

    Nov 1, 2019, 00:00

  • PDB35 COST-EFFECTIVENESS OF GLICLAZIDE MR-BASED INTENSIVE GLUCOSE CONTROL VERSUS STANDARD GLUCOSE CONTROL IN TYPE 2 DIABETES MELLITUS. AN ECONOMIC ANALYSIS IN VIETNAM OF THE ADVANCE TRIAL

    Nov 1, 2019, 00:00

  • PRO10 QUALITATIVE STUDY TO ESTABLISH THE CONTENT VALIDITY OF THE ABC-CFXS FOR EVALUATION OF TREATMENT EFFICACY IN FRAGILE X SYNDROME

    Nov 1, 2019, 00:00

  • PRS71 NEW METHODS FOR ANALYZING CLINICAL AND COST OUTCOMES IN ASTHMA WITH INTERACTIVE VISUAL ANALYTICS

    Nov 1, 2019, 00:00

  • PGI50 THE RELATIONSHIP BETWEEN DISEASE SEVERITY AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS IN JAPAN

    Nov 1, 2019, 00:00

  • PCN139 BUDGET IMPACT ANALYSIS OF NILOTINIB AS FIRST LINE TREATMENT OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) WITH HIGH RISK SOKAL SCORE IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00

  • PDB76 IMPACT OF COPAYMENT INCREASE OF ANTIDIABETIC MEDICATIONS ON GLYCAEMIC CONTROL IN FINNISH PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2019, 00:00

  • PPM6 HEALTH ECONOMICS MODEL OF FOUNDATIONONE CDX® IN LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN TURKEY

    Nov 1, 2019, 00:00

  • PMU121 CRITICAL REVIEW OF VALIDATION STUDIES OF ARTIFICIAL INTELLIGENCE TECHNOLOGIES APPLIED IN MEDICINE DURING THE LAST FIVE YEARS

    Nov 1, 2019, 00:00

  • PNS370 METHODS AND CONSIDERATIONS FOR THE DEVELOPMENT, CONTENT VALIDITY TESTING, AND EVALUATION OF PATIENT EDUCATION TOOLS (PETS)

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PCN153 OVERVIEW OF ECONOMIC EVALUATIONS OF ONCOLOGY PRODUCTS WITH A FOCUS ON THE KEY CHALLENGES ACROSS, UNITED KINGDOM, FRANCE AND CANADA

    Nov 1, 2019, 00:00

  • PCN175 BUDGET IMPACT ANALYSIS OF THE INCORPORATION OF MIDOSTAURIN FOR FLT3-POSITIVE ACUTE MYELOID LEUKEMIA (AML) IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM (BPHS).

    Nov 1, 2019, 00:00

  • PDB43 COST COMPARISON OF GLICAZIDE MODIFIED-RELEASE AND GENERIC GLICLAZIDE IN PREVENTING END STAGE RENAL DISEASE IN TYPE 2 DIABETES MELLITUS IN THE PUBLIC SECTOR OF MALAYSIA

    Nov 1, 2019, 00:00

  • PCV46 BUDGET IMPACT OF A DUAL-LAYER STENT RETRIEVER (DLSR) IN THE TREATMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE (AIS) FROM HOSPITAL'S PERSPECTIVE IN FRANCE AND SWEDEN

    Nov 1, 2019, 00:00

  • PIN14 HEALTH UTILITY ESTIMATES FOR CONGENITAL CYTOMEGALOVIRUS DISEASE: CONCEPTUAL DESIGN CONSIDERATIONS

    Nov 1, 2019, 00:00

  • PDG69 DEVELOPMENT OF LISTS OF TOPICAL ANTIFUNGAL DRUGS INCLUDED INTO THE ALL EDITIONS OF STATE FORMULARY OF UKRAINE

    Nov 1, 2019, 00:00

  • PCN96 COST-EFFECTIVENESS OF TREATMENT SEQUENCES FOR BRAF WILD-TYPE METASTATIC MELANOMA IN REAL LIFE IN FRANCE

    Nov 1, 2019, 00:00

  • PNS53 REVIEW OF METHODOLOGICAL QUALITY OF BUDGET IMPACT ANALYSES FOR ORPHAN DRUGS

    Nov 1, 2019, 00:00

  • PRO3 TREATMENT PATTERNS AND OUTCOMES ASSOCIATED WITH THE USE OF PONATINIB IN CLINICAL PRACTICE: A QUALITATIVE SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN36 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY: A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PMU139 VALIDITY OF THE SLOVENIAN VERSION OF THE CARERQOL-7D QUESTIONNAIRE AMONG INFORMAL CAREGIVERS IN THE SLOVENIAN GENERAL POPULATION

    Nov 1, 2019, 00:00

  • PMU50 UNFOLD THE MYSTERY OF PRICE NEGOTIATION IN CHINA: HOW REIMBURSEMENT PAYMENT STANDARD WAS FORMULATED

    Nov 1, 2019, 00:00

  • Drugs Generics - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PCN117 COST-UTILITY ANALYSIS OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY VERSUS TRASTUZUMAB AND CHEMOTHERAPY FOR THE ADJUVANT TREATMENT OF PATIENTS WITH HER2+ EARLY BREAST CANCER IN SPAIN

    Nov 1, 2019, 00:00

  • PCN16 ASSESSMENT OF THE QUALITY OF LIFE, PHYSICAL ACTIVITY, DEPRESSION AND ANXIETY OF PATIENTS UNDER ONCOLOGY CARE

    Nov 1, 2019, 00:00

  • PCV141 ATHEROSCLEROSIS: REAL-WORLD INSIGHTS FROM A PORTUGUESE PRIMARY CARE DATABASE

    Nov 1, 2019, 00:00

  • Cancer - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PCV93 RESOURCE USE AND COSTS OF ACUTE CORONARY SYNDROME: A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCV6 BURDEN OF MORTALITY IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION - A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN353 RECENT HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS ACROSS THE GLOBE: A FOCUS ON NON-SMALL CELL LUNG CANCER: RESULTS, RATIONALE, AND TRENDS

    Nov 1, 2019, 00:00

  • PGI23 COST OF INFLAMMATORY BOWEL DISEASE MANAGEMENT IN THE KINGDOM OF SAUDI ARABIA

    Nov 1, 2019, 00:00

  • Infectious Diseases - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PND106 LIVING WITH MIGRAINE: SUPPORT NEEDED AND HEALTHCARE EXPENDITURE ON BRAZILIAN PATIENTS FROM THE MY MIGRAINE VOICE SURVEY

    Nov 1, 2019, 00:00

  • PCV99 UNDERSTANDING POST DISCHARGE MANAGEMENT AFTER AN ACUTE MYOCARDIAL INFARCTION IN ITALY: REGIONAL PATHWAYS AND OUTCOME INDEX

    Nov 1, 2019, 00:00

  • PRS10 UNDERSTANDING EMPHYSEMA BURDEN AND TREATMENT PATTERNS IN THE UNITED STATES: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCV73 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS WARFARIN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION IN THE JAPANESE HEALTHCARE SETTING

    Nov 1, 2019, 00:00

  • PNS137 ORPHAN DRUGS: WHAT FACTORS IMPACT THE PRICE IN FRANCE?

    Nov 1, 2019, 00:00

  • PMU52 ANALYSIS OF THE REIMBURSEMENT DECISIONS MADE BY THE INTERMINISTERIAL PRICE COMMISSION FOR MEDICINES IN SPAIN

    Nov 1, 2019, 00:00

  • PSY28 EPIDEMIOLOGY OF ATOPIC DERMATITIS IN SCHOOLCHILDREN AND ADOLESCENTS IN ITALY: A SYSTEMATIC REVIEW OF THE LITERATURE

    Nov 1, 2019, 00:00

  • PCN293 POST-PROGRESSION ENDPOINTS IN ONCOLOGY TRIALS: CURRENT CLINICAL AND REIMBURSEMENT PERSPECTIVES

    Nov 1, 2019, 00:00

  • PNS38 PROPOSING AND EVALUATING A DESIGN FOR GDPR-COMPLIANT, SCALABLE TECHNOLOGY FOR AUTOMATIC ADJUDICATION OF RISK-SHARING AGREEMENTS

    Nov 1, 2019, 00:00

  • PCV66 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF ARTERIAL EMBOLISM AND THROMBOSIS IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PIN4 A NETWORK META-ANALYSIS OF THE EFFICACY AND SAFETY OF BALOXAVIR MARBOXIL VERSUS NEURAMINIDASE INHIBITORS IN THE TREATMENT OF INFLUENZA VIRUS INFECTION IN OTHERWISE HEALTHY AND HIGH-RISK ADULTS

    Nov 1, 2019, 00:00

  • PR3 HOME-BASED ASSESSMENT OF PATIENT REPORTED OUTCOME MEASURES USING A SMARTPHONE APP PLATFORM: A FEASIBILITY STUDY

    Nov 1, 2019, 00:00

  • PIN60 COMPARISON OF ANTI-HIV AND ANTI-HCV THERAPY COSTS IN THE CZECH REPUBLIC

    Nov 1, 2019, 00:00

  • PCN327 KEY INTERVALS IN THE PATIENT JOURNEY OF MEN WITH PROSTATE CANCER: EVIDENCE FROM GREECE

    Nov 1, 2019, 00:00

  • PRO39 CONCEPTUAL FRAMEWORK FOR EVALUATING THE COST-EFFECTIVENESS OF A GENE THERAPY FOR HAEMOPHILIA B

    Nov 1, 2019, 00:00

  • PIN70 COST-EFFECTIVENESS OF SEASONAL VACCINATION WITH QUADRIVALENT INFLUENZA VACCINE IN PORTUGAL

    Nov 1, 2019, 00:00

  • PCN500 REAL-WORLD TREATMENT PATTERNS AND OUTCOMES FOR PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA RECEIVING SYSTEMIC THERAPY IN BRAZIL

    Nov 1, 2019, 00:00

  • PCN239 MEDICAL COST OF RITUXIMAB-CONTAINING THERAPY IN PATIENTS WITH FOLLICULAR LYMPHOMA IN JAPAN: R-B IS LESS EXPENSIVE THAN R-CHOP

    Nov 1, 2019, 00:00

  • Individual's Health - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PCN259 SKELETAL ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS: EMERGING TRENDS FROM THE US FOOD AND DRUG ADMINISTRATION ADVERSE EVENT REPORTING SYSTEM

    Nov 1, 2019, 00:00

  • PMS59 REAL-WORLD EFFECTIVENESS OF PHYSIOTHERAPY INTERVENTIONS FOR MUSCULOSKELETAL DISORDERS IN NIGERIA

    Nov 1, 2019, 00:00

  • PUK30 COMPARING SOFTWARE FOR PATIENT-LEVEL SIMULATION: REPLICATING A MODEL OF HYPERPHOSPHATAEMIA IN CHRONIC KIDNEY DISEASE

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PND72 EVOLUTION OF THE CONSUMPTION OF ANTIEPILETEC DRUGS IN MOROCCO FROM 2004 TO 2016

    Nov 1, 2019, 00:00

  • PMU130 REPRESENTATIVENESS OF THE NATIONAL HEALTH AND WELLNESS SURVEY IN EUROPE: CURRENT EPIDEMIOLOGY ACROSS MULTIPLE DISEASES

    Nov 1, 2019, 00:00

  • PIN77 EFFICACY MISAPPLICATION IN VACCINE MODELLING

    Nov 1, 2019, 00:00

  • PNS103 PHARMACY RESEARCH BASIC KNOWLEDGE IN THE KINDOM OF SAUDI ARABIA

    Nov 1, 2019, 00:00

  • PMS38 COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB SC IN COMPARISON WITH ANAKINRA IN SYSTEMIC IDIOPATHIC JUVENILE ARTHRITIS (SJIA) TREATMENT IN TURKEY

    Nov 1, 2019, 00:00

  • PCN185 PERTUZUMAB RISK SHARING AGREEMENT IN THE PORTUGUESE NHS: A 4-YEAR EXPERIENCE

    Nov 1, 2019, 00:00

  • Medical Devices - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PMU143 PATIENT CENTRICITY IN PATIENT PREFERENCE STUDIES: INTERVIEWS WITH PATIENTS

    Nov 1, 2019, 00:00

  • Mental Health - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PCV100 THE RELATIONSHIP BETWEEN PROCEDURAL VOLUME AND POSTOPERATIVE MORTALITY FOR PERCUTANEOUS CORONARY INTERVENTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PND101 AN UPDATE OF A SYSTEMATIC REVIEW: ATTRIBUTE BASED STATED PREFERENCE STUDIES IN MULTIPLE SCLEROSIS PATIENTS

    Nov 1, 2019, 00:00

  • PMD20 COST EFFECTIVENESS ANALYSIS OF IMPLANTABLE CARDIAC MONITORS TO DETECT ATRIAL FIBRILLATION AFTER CRYPTOGENIC STROKE

    Nov 1, 2019, 00:00

  • PNS397 PATIENTS' PERCEPTION OF THE QUALITY OF CONSULTATIONS MODELLED BY PATIENT-REPORTED EXPERIENCE AND HEALTH-RELATED QUALITY OF LIFE MEASURES

    Nov 1, 2019, 00:00

  • PDG104 DECREASING NUMBER OF PRESCRIPTIONS AFTER THEY BECAME MANDATORY AND THEIR VALIDITY PERIOD WAS EXTENDED TO TWO YEARS: CASE FINLAND SINCE 2017

    Nov 1, 2019, 00:00

  • PNS6 SYSTEMATIC LITERATIVE REVIEW AND QUALITATIVE ANALYSIS ASSESSING EFFICACY AND SAFETY OF INTERVENTIONS IN ACTINIC KERATOSIS

    Nov 1, 2019, 00:00

  • PCN304 REIMBURSEMENT AND PAYER MANAGEMENT OF IMMUNE CHECKPOINT INHIBITORS IN KEY EUROPEAN MARKETS

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PCN218 COST-EFFECTIVENESS OF APALUTAMIDE + ADT VERSUS ENZALUTAMIDE + ADT IN NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER IN GREECE

    Nov 1, 2019, 00:00

  • PGI30 THE MEDICAL COSTS OF INFLAMMATORY BOWEL DISEASE IN RUSSIA FROM A PUBLIC PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PSY44 ECONOMIC BURDEN OF MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) TO PATIENTS: COMPARATIVE STUDY

    Nov 1, 2019, 00:00

  • PCN299 MINIMUM VOLUME STANDARDS IN FRENCH HOSPITALS FOR BREAST CANCER AND OVARIAN CANCER - INEQUALITIES IN ACCESS TO HOSPITAL CARE

    Nov 1, 2019, 00:00

  • PCN496 BURDEN OF ACUTE MYELOID LEUKEMIA AMONG NEWLY DIAGNOSED PATIENTS IN SOUTH KOREA: RETROSPECTIVE EMR DATABASE ANALYSIS

    Nov 1, 2019, 00:00

  • PCN460 SYSTEMATIC LITERATURE REVIEW FOR UTILITY DATA IN ACUTE MYELOID LEUKEMIA

    Nov 1, 2019, 00:00

  • PMU138 EXPLORATIVE SCOPING REVIEW AND BIBLIOMETRIC ANALYSIS OF BIG DATA APPLICATIONS FOR MEDICATION ADHERENCE

    Nov 1, 2019, 00:00
  • «
  • 51 (current)
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • »